NCT04607512 is a Phase 1 clinical trial of telaglenastat in Cardiac Safety, sponsored by Calithera Biosciences, Inc.

Who is sponsoring NCT04607512?

NCT04607512 is sponsored by Calithera Biosciences, Inc.

What drugs are being tested in NCT04607512?

Interventions in NCT04607512: telaglenastat, telaglenastat placebo, moxifloxicin.

What condition does NCT04607512 study?

NCT04607512 studies Cardiac Safety.

Is NCT04607512 still recruiting?

NCT04607512 is currently completed. Last updated 9 March 2021.

Last reviewed 2021-03-09 · How we verify

NCT04607512

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

Completed Phase 1 Last updated 9 March 2021

What this trial tests

Phase 1 trial testing telaglenastat in Cardiac Safety in 30 participants. Completed in 30 December 2020.

Timeline

5 October 2020

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Calithera Biosciences, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	30
Start date	5 October 2020
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

telaglenastat — full drug profile →
telaglenastat placebo
moxifloxicin

Conditions studied

Cardiac Safety — all drugs for Cardiac Safety →

Sponsor

Calithera Biosciences, Inc — full company profile →

Who can join

Adults 18 to 45, any sex, with Cardiac Safety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the effects of telaglenastat on cardiac repolarization (relative to placebo) in healthy adult subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery.
Giesen B, Nickel AC, Barthel J, Kahlert UD, et al · · 2021 · cited 13× · PMID 33672398 · DOI 10.3390/pharmaceutics13020295
Metabolism in the tumor microenvironment: implications for pathogenesis and therapeutics.
Wik JA, Berge ER, Stromsnes K, Skålhegg BS. · · 2025 · cited 1× · PMID 41235226 · DOI 10.3389/fimmu.2025.1610255

Verify or expand the search:

Other Calithera Biosciences, Inc trials

Trials by the same sponsor.

NCT05319028 — Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · Phase 2 · terminated
NCT04698681 — NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial · terminated
NCT04540965 — Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects · Phase 1 · completed
NCT04265534 — KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamo · Phase 2 · terminated
NCT04279769 — Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04607512 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Calithera Biosciences, Inc
Last refreshed: 9 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04607512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing